Abstract
Alternative splicing evolved as a very efficient way to generate proteome diversity and to regulate cell homeostasis from a limited number of genes. Moreover, changes in the relative amounts of different splice variants derived from the same pre-mRNA are a hallmark in cancer, and aberrant expression of alternatively spliced mRNAs has been linked to cancer initiation and progression. Therefore, splice variants are critical tools to assess disease progression and clinical prognosis, and hold great promise as potential targets for therapeutic intervention. In order to understand the role that such splice variants play in cancer, it is vital to be able to accurately quantify their expression levels in different cell types and organs, both in normal conditions and in disease. In this chapter we describe a protocol to efficiently detect, analyze, and quantify alternative splicing patterns of immune mediators such as chemokines, cytokine and their receptors and ligands in cancer by quantitative PCR.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Quackenbush J (2001) The power of public access: the human genome project and the scientific process. Nat Genet 29:4–6
Venter JC, Adams MD, Myers EW et al (2001) The sequence of the human genome. Science 291:1304–1351
Samuels DC, Han L, Li J et al (2013) Finding the lost treasures in exome sequencing data. Trends Genet 29:593–599
Wang ET, Sandberg R, Luo S et al (2008) Alternative isoform regulation in human tissue transcriptomes. Nature 456:470–476
Pan Q, Shai O, Lee LJ et al (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40:1413–1415
Nilsen TW, Graveley BR (2010) Expansion of the eukaryotic proteome by alternative splicing. Nature 463:457–463
Modrek B, Resch A, Grasso C et al (2001) Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res 29:2850–2859
Black DL (2003) Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 72:291–336
López-Bigas N, Audit B, Ouzounis C et al (2005) Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett 579:1900–1903
Cooper TA, Wan L, Dreyfuss G (2009) RNA and disease. Cell 136:777–793
Singh RK, Cooper TA (2012) Pre-mRNA splicing in disease and therapeutics. Trends Mol Med 18:472–482
Lynch KW (2004) Consequences of regulated pre-mRNA splicing in the immune system. Nat Rev Immunol 4:931–940
Martinez NM, Pan Q, Cole BS et al (2012) Alternative splicing networks regulated by signaling in human T cells. RNA 18:1029–1040
Martinez NM, Lynch KW (2013) Control of alternative splicing in immune responses: many regulators, many predictions, much still to learn. Immunol Rev 253:216–236
Yabas M, Elliott H, Hoyne GF (2015) The role of alternative splicing in the control of immune homeostasis and cellular differentiation. Int J Mol Sci 17:E3
Schaub A, Glasmacher E (2017) Splicing in immune cells-mechanistic insights and emerging topics. Int Immunol 29:173–181
Kim E, Goren A, Ast G (2008) Insights into the connection between cancer and alternative splicing. Trends Genet 24:7–10
Bruikman CS, Zhang H, Kemper AM et al (2019) Netrin family: role for protein isoforms in cancer. J Nucleic Acids 2019:3947123
Li D, Harlan-Williams LM, Kumaraswamy E et al (2019) BRCA1-no matter how you splice it. Cancer Res 79:2091–2098
Hagen RM, Ladomery MR (2012) Role of splice variants in the metastatic progression of prostate cancer. Biochem Soc Trans 40:870–874
Wang BD, Lee NH (2018) Aberrant RNA splicing in cancer and drug resistance. Cancers (Basel) 10:E458
Coltri PP, Dos Santos MGP, da Silva GHG (2019) Splicing and cancer: challenges and opportunities. Wiley Interdiscip Rev RNA 10:e1527
Angiolini F, Belloni E, Giordano M et al (2019) A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing. Elife 8:e44305
Stevens M, Oltean S (2019) Modulation of receptor tyrosine kinase activity through alternative splicing of ligands and receptors in the VEGF-A/VEGFR axis. Cells 8:E288
Itoh N, Yonehara S, Ishii A et al (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233–243
Cascino I, Papoff G, Eramo A et al (1996) Soluble Fas/Apo-1 splicing variants and apoptosis. Front Biosci 1:d12–d18
Villamizar O, Chambers CB, Riberdy JM et al (2016) Long noncoding RNA Saf and splicing factor 45 increase soluble Fas and resistance to apoptosis. Oncotarget 7:13810–13826
Fu Y, Wang Y (2018) SRSF7 knockdown promotes apoptosis of colon and lung cancer cells. Oncol Lett 15:5545–5552
Cheng J, Zhou T, Liu C et al (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759–1762
Cascino I, Fiucci G, Papoff G et al (1995) Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 154:2706–2713
Kischkel FC, Hellbardt S, Behrmann I et al (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14:5579–5588
Ashkenazi A, Dixit VM (1999) Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11:255–260
Ueno T, Toi M, Tominaga T (1999) Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res 5:3529–3533
Sheen-Chen SM, Chen HS, Eng HL et al (2003) Circulating soluble Fas in patients with breast cancer. World J Surg 27:10–13
Natoli G, Ianni A, Costanzo A et al (1995) Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 11:1157–1164
Owen-Schaub LB, Angelo LS, Radinsky R et al (1995) Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis. Cancer Lett 94:1–8
Lasagni L, Francalanci M, Annunziato F et al (2003) An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 197:1537–1549
Dagan-Berger M, Feniger-Barish R, Avniel S et al (2006) Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion and internalization in response to CXCL11. Blood 107:3821–3831
Romagnani P, Annunziato F, Lazzeri E et al (2001) Interferon-inducible protein 10, monokine induced by interferon gamma, and interferon-inducible T-cell alpha chemoattractant are produced by thymic epithelial cells and attract T-cell receptor (TCR) alphabeta+ CD8+ single-positive T cells, TCRgammadelta+ T cells, and natural killer-type cells in human thymus. Blood 97:601–607
Martín-Fontecha A, Thomsen LL, Brett S et al (2004) Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 5:1260–1265
Bodnar RJ, Yates CC, Wells A (2006) IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circ Res 98:617–625
Wu Q, Dhir R, Wells A (2012) Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer 11:3
Berchiche YA, Sakmar TP (2016) CXC chemokine receptor 3 alternative splice variants selectively activate different signaling pathways. Mol Pharmacol 90:483–495
Smit MJ, Verdijk P, van der Raaij-Helmer EM et al (2003) CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C-dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase. Blood 102:1959–1965
Satish L, Blair HC, Glading A et al (2005) Interferon-inducible protein 9 (CXCL11)-induced cell motility in keratinocytes requires calcium flux-dependent activation of mu-calpain. Mol Cell Biol 25:1922–1941
Kouroumalis A, Nibbs RJ, Aptel H et al (2005) The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate G alpha i-independent signaling and actin responses in human intestinal myofibroblasts. J Immunol 175:5403–5411
Thompson BD, Jin Y, Wu KH et al (2007) Inhibition of G alpha i2 activation by G alpha i3 in CXCR3-mediated signaling. J Biol Chem 282:9547–9555
Petrai I, Rombouts K, Lasagni L et al (2008) Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B. Int J Biochem Cell Biol 40:1764–1774
Kruse JP, Gu W (2009) Modes of p53 regulation. Cell 137:609–622
Yin Y, Stephen CW, Luciani MG et al (2002) p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 4:462–467
Courtois S, Verhaegh G, North S et al (2002) DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21:6722–6728
Maier B, Gluba W, Bernier B et al (2004) Modulation of mammalian life span by the short isoform of p53. Genes Dev 18:306–319
Ghosh A, Stewart D, Matlashewski G (2004) Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 24:7987–7997
Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4:33–45
Yin T, Wang G, He S et al (2016) Human cancer cells with stem cell-like phenotype exhibit enhanced sensitivity to the cytotoxicity of IL-2 and IL-15 activated natural killer cells. Cell Immunol 300:41–45
Chen C, Zhao S, Karnad A et al (2018) The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 11:64
Tölg C, Hofmann M, Herrlich P et al (1993) Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res 21:1225–1229
Screaton GR, Bell MV, Jackson DG et al (1992) Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci U S A 89:12160–12164
Screaton GR, Bell MV, Bell JI et al (1993) The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat. J Biol Chem 268:12235–12238
Cheng C, Sharp PA (2006) Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol Cell Biol 26:362–370
Yae T, Tsuchihashi K, Ishimoto T et al (2012) Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun 3:883
Prochazka L, Tesarik R, Turanek J (2014) Regulation of alternative splicing of CD44 in cancer. Cell Signal 26:2234–2239
Orian-Rousseau V, Chen L, Sleeman JP et al (2002) CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16:3074–3086
Todaro M, Gaggianesi M, Catalano V et al (2014) CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14:342–356
Kaufmann M, Heider KH, Sinn HP et al (1995) CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345:615–619
Magyarosy E, Sebestyén A, Timár J (2001) Expression of metastasis associated proteins, CD44v6 and NM23-H1, in pediatric acute lymphoblastic leukemia. Anticancer Res 21:819–823
Shakola F, Byrne S, Javed K et al (2014) Radiolabeled semi-quantitative RT-PCR assay for the analysis of alternative splicing of interleukin genes. Methods Mol Biol 1172:343–362
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25:402–408
Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
Rao X, Huang X, Zhou Z et al (2013) An improvement of the 2(−delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinform Biomath 3:71–85
Acknowledgment
This work was supported by NIH grant 1R15GM119099-01 to M. Ruggiu.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Wang, R., Hossain, M.F., Mirkovic, J., Sabzanov, S., Ruggiu, M. (2020). Real-Time PCR Assay for the Analysis of Alternative Splicing of Immune Mediators in Cancer. In: Vancurova, I., Zhu, Y. (eds) Immune Mediators in Cancer. Methods in Molecular Biology, vol 2108. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0247-8_21
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0247-8_21
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0246-1
Online ISBN: 978-1-0716-0247-8
eBook Packages: Springer Protocols